JP2016014007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016014007A5 JP2016014007A5 JP2015086165A JP2015086165A JP2016014007A5 JP 2016014007 A5 JP2016014007 A5 JP 2016014007A5 JP 2015086165 A JP2015086165 A JP 2015086165A JP 2015086165 A JP2015086165 A JP 2015086165A JP 2016014007 A5 JP2016014007 A5 JP 2016014007A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine
- group
- isoleucine
- leucine
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 tyrosine compound Chemical class 0.000 claims 17
- 229960000310 ISOLEUCINE Drugs 0.000 claims 11
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- 210000003205 Muscles Anatomy 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 235000013361 beverage Nutrition 0.000 claims 4
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 claims 3
- 108010016626 Dipeptides Proteins 0.000 claims 3
- 102000008934 Muscle Proteins Human genes 0.000 claims 3
- 108010074084 Muscle Proteins Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 230000000865 phosphorylative Effects 0.000 claims 3
- 238000001243 protein synthesis Methods 0.000 claims 3
- 230000001225 therapeutic Effects 0.000 claims 3
- 230000014616 translation Effects 0.000 claims 3
- 150000003668 tyrosines Chemical class 0.000 claims 3
- 230000003387 muscular Effects 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (14)
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、
を有効成分とする、筋タンパク質合成シグナル活性化剤。 At least one tyrosine compound, and at least one amino acid selected from the group consisting of leucine and isoleucine,
A muscle protein synthesis signal activator comprising as an active ingredient.
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、
を有効成分とする、ｐ７０Ｓ６キナーゼのリン酸化促進剤。 At least one tyrosine compound, and at least one amino acid selected from the group consisting of leucine and isoleucine,
A phosphorylation promoter for p70S6 kinase, comprising
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、
を有効成分とする、筋量改善剤。 At least one tyrosine compound, and at least one amino acid selected from the group consisting of leucine and isoleucine,
An agent for improving muscle mass, comprising
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、
を有効成分とする、筋力改善剤。 At least one tyrosine compound, and at least one amino acid selected from the group consisting of leucine and isoleucine,
A muscular strength-improving agent comprising
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、
を有効成分とする、筋萎縮抑制剤。 At least one tyrosine compound, and at least one amino acid selected from the group consisting of leucine and isoleucine,
A muscular atrophy inhibitor comprising
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、
それぞれを有効量投与又は摂取させる、非治療的筋タンパク質合成シグナル活性化方法、非治療的ｐ７０Ｓ６キナーゼのリン酸化促進方法、非治療的筋量改善方法、非治療的筋力改善方法、又は非治療的筋萎縮抑制方法。 At least one tyrosine compound, and at least one amino acid selected from the group consisting of leucine and isoleucine,
Non-therapeutic muscle protein synthesis signal activation method, non-therapeutic p70S6 kinase phosphorylation promotion method, non-therapeutic muscle mass improvement method, non-therapeutic muscle strength improvement method, or non-therapeutic method A method for suppressing muscle atrophy.
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、 At least one amino acid selected from the group consisting of leucine and isoleucine,
を有効成分として含有する、筋タンパク質合成シグナル活性化用飲食品組成物。A food / beverage product composition for activating muscle protein synthesis signal, comprising as an active ingredient.
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、 At least one amino acid selected from the group consisting of leucine and isoleucine,
を有効成分として含有する、ｐ７０Ｓ６キナーゼのリン酸化促進用飲食品組成物。A food and drink composition for promoting phosphorylation of p70S6 kinase, comprising
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、 At least one amino acid selected from the group consisting of leucine and isoleucine,
を有効成分として含有する、筋量改善用飲食品組成物。A food / beverage composition for improving muscle mass, comprising as an active ingredient.
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、 At least one amino acid selected from the group consisting of leucine and isoleucine,
を有効成分として含有する、筋力改善用飲食品組成物。A food / beverage composition for improving muscular strength, comprising:
ロイシン及びイソロイシンからなる群より選ばれる少なくとも１種のアミノ酸、 At least one amino acid selected from the group consisting of leucine and isoleucine,
を有効成分として含有する、筋萎縮抑制用飲食品組成物。The food-drinks composition for a muscular atrophy suppression which contains as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015086165A JP6496599B2 (en) | 2014-06-13 | 2015-04-20 | Muscle protein synthesis signal activator |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014122669 | 2014-06-13 | ||
| JP2014122669 | 2014-06-13 | ||
| JP2015086165A JP6496599B2 (en) | 2014-06-13 | 2015-04-20 | Muscle protein synthesis signal activator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016014007A JP2016014007A (en) | 2016-01-28 |
| JP2016014007A5 true JP2016014007A5 (en) | 2018-04-26 |
| JP6496599B2 JP6496599B2 (en) | 2019-04-03 |
Family
ID=55230521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015086165A Active JP6496599B2 (en) | 2014-06-13 | 2015-04-20 | Muscle protein synthesis signal activator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6496599B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7008452B2 (en) | 2017-09-25 | 2022-01-25 | 花王株式会社 | Highly absorbable oral tyrosine preparation |
| WO2020130146A1 (en) * | 2018-12-21 | 2020-06-25 | 味の素株式会社 | Agent for improving muscle quality |
| JP7462127B1 (en) | 2023-08-16 | 2024-04-05 | 株式会社Healthy Body | Muscle Hypertrophy Composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2518692B2 (en) * | 1989-06-14 | 1996-07-24 | 理化学研究所 | Muscle maintenance agent, nutrient tonic, infusion agent, nutritional supplement, fatigue recovery agent and lactic acid production regulator |
| JP4528925B2 (en) * | 2003-05-30 | 2010-08-25 | 独立行政法人理化学研究所 | Amino acid composition and fluid replacement |
| JP5775657B2 (en) * | 2006-06-13 | 2015-09-09 | 株式会社明治 | Anti-fatigue agent containing amino acid composition |
| CN104922115A (en) * | 2007-10-31 | 2015-09-23 | 株式会社明治 | Anti-fatigue agent comprising amino acid composition |
| JPWO2010041647A1 (en) * | 2008-10-06 | 2012-03-08 | 株式会社明治 | Endurance improver, fatigue inhibitor, or fatigue recovery agent comprising an amino acid composition as an active ingredient |
-
2015
- 2015-04-20 JP JP2015086165A patent/JP6496599B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011974A (en) | Stabilisation of 1-chloro-3,3,3-trifluoropropene. | |
| WO2018175258A8 (en) | Methods and compositions for preparing nucleic acid libraries | |
| WO2016094702A3 (en) | Methods for modulating taste receptors | |
| MX2018001205A (en) | Inhibitor of the mutated isocitrate dehydrogenase idh1 r132h. | |
| NZ745210A (en) | Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor | |
| TW200734306A (en) | Novel compounds, their preparation and use | |
| GB2597577B (en) | Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen | |
| EP4218736A3 (en) | Compositions comprising 15-hepe | |
| JP2016014007A5 (en) | ||
| PH12017501397B1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| PH12017501444A1 (en) | (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
| EP4066835A4 (en) | Use of composition for enhancing anticancer effect, comprising err-gamma inhibitor as active ingredient | |
| EP3564224A3 (en) | Crystalline form of vortioxetine hydrobromide as antidepressant drug | |
| PH12020500074A1 (en) | Peptide | |
| UA94716C2 (en) | Calcium-peptide component for reducing body weight | |
| WO2016076607A3 (en) | Pharmaceutical composition and health functional food, containing a red ginseng concentrate with enriched compound k component, for preventing and treating non-alcoholic fatty liver symptom | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| PH12018500433A1 (en) | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | |
| JP2014201572A5 (en) | ||
| JP2016160183A5 (en) | Muscle atrophy inhibitor and food and drink for muscle atrophy suppression | |
| WO2012126686A3 (en) | Saffron odorants | |
| WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
| WO2016189385A3 (en) | Enhanced salt compositions and methods of preparation thereof | |
| WO2010041827A3 (en) | NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME | |
| JP2014101346A5 (en) |